The guidance now specifies updated methodologies for assessing skin irritation and sensitization in clinical studies associated with ANDAs, including new clinical endpoint parameters and reporting obligations related to localized adverse reactions.
Compliance with these revised expectations is critical for ensuring the safety and efficacy of generic topical products and maintaining consistency in safety reporting protocols.
Clinical safety and pharmacovigilance teams must update their study protocols and adverse event reporting procedures to align with the revised guidance by October 2, 2026.
Regulatory Intelligence Lead
Review before 2026-10-02.
Updates to study design parameters, clinical endpoints for irritation and sensitization, and reporting expectations for localized safety data in Abbreviated New Drug Applications (ANDAs).
Clinical safety and PV operations teams involved in TDS development must update their study protocols and adverse event collection procedures to align with the revised criteria for irritation and sensitization scoring. This ensuring that safety reporting for generic topical products is consistent with FDA's updated expectations for local tolerability data.
Clinical safety and pharmacovigilance teams must update their study protocols and adverse event reporting procedures to align with the revised guidance by October 2, 2026.
The FDA has released a revised draft guidance for industry detailing study designs to assess the irritation and sensitization potential of transdermal and topical delivery systems (TDS) for abbreviated new drug applications (ANDAs). This updated guidance includes new parameters for study design, clinical endpoints, and reporting expectations, particularly focusing on localized adverse reactions. The guidance is intended to align generic product safety reporting with current FDA expectations.
What changed: The guidance now specifies updated methodologies for assessing skin irritation and sensitization in clinical studies associated with ANDAs, including new clinical endpoint parameters and reporting obligations related to localized adverse reactions.
Why it matters: Compliance with these revised expectations is critical for ensuring the safety and efficacy of generic topical products and maintaining consistency in safety reporting protocols.
Practical implication: Clinical safety and pharmacovigilance teams must update their study protocols and adverse event reporting procedures to align with the revised guidance by October 2, 2026.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
